Market Risk Analysis Brief for Asthma and Chronic Obstructive Pulmonary Disease Drugs.

The respiratory system is the general designation of a series of organs in which the body exchanges gases with the outside air, including the nose, pharynx, throat, trachea, bronchial tubes and lungs consisting of a large number of alveums, blood vessels, lymphatic tubes, nerves, and thoracic membranes.
commonly refers to the nose, pharynx and throat as the upper respiratory tract, and the gas channels below the trachea (including bronchial tubes at all levels of the lungs) are referred to as the lower respiratory tract.
cardiovascular disease, tumor and respiratory diseases are the top three diseases of human death, and asthma and chronic obstructive pulmonary disease (COPD) are the most common chronic respiratory diseases.
China's respiratory drug market is mainly composed of anti-asthma drugs, phlegm drugs, cough medicine, cold medicine, COPD medication, respiratory excitatory drugs and other respiratory drugs, of which asthma and COPD drugs are the most important segments.
the exacerbation of air pollution led to bronchitis, asthma, emphysema and other diseases, leading to asthma treatment drugs, cold cough medication demand for a faster increase.
asthma and COPD drugs have long been monopolized by AstraZeneta, Grigg Ingeham, GlaxoSmithKline and TEVA (Figure 1), with china's major asthma and COPD drugs worth about 2.762 billion yuan in 2018.
With the technological progress of domestic enterprises on the technical barriers to inhalation preparations, the expiration of patents for pharmaceuticals, more enterprises have joined this field, such as the current Budinide generic drugs approved for listing of enterprises including: Lunanbete, Shanghai Pharmaceutical Xinyi, People's Fu Pharmaceuticals, Zhengda Tianqing and Mrs. Pharmaceuticals.
1:2018COPD:99.58%12.53:0.42%+:100%4.05:66.06%2.95:29.58%:3.43%+:100%2.65:99.65%1.49:0.35%:44.5%1.13:36.11%:17.66%:100%1.06+:100%0.92:98.37%0.60:1.45%:100。 %024 million Source: China Pharmaceutical Industry Information Center, SGRCR finishing 1. Manufacturing technical barriers high asthma and COPD drug generic drugs, technical barriers are not limited to the drug itself, inhalation type technical barriers are higher, production costs, testing costs and equipment costs are high, domestic asthma and COPD inhalation preparations market has long been monopolized by foreign enterprises.
Inhalers consist of main drugs, accessories, pressure-resistant containers, quantitative valve systems and injection devices, and quality control indicators include the particle size and particle size distribution of the drug, injection mode, the content of each main spray and the total spray per bottle, etc., and the different filling processes directly affect product quality.
local companies such as Lunambet and Shanghai Pharmaceuticals are now able to produce inhaler-type Budinide.
2. Despite the rapid expansion of the asthma and COPD drug markets in recent years, the market size is now less than 3 billion yuan per year, the market size is still small.
due to large upfront investment and slow returns, generally only large pharmaceutical companies have the ability to lay out asthma and COPD drugs.
3. The lack of impetus for research and development of new drugs due to the overall size of the market, and such as Budinide, ammonium seto bromide and salbutamol and other drugs have good results, no good response, foreign enterprises in new drug research and development investment lack of motivation, local enterprises in respiratory drug research and development gap is greater, still mainly to produce generic drugs.
.